Abstract: Pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with biological activity allow for the provision of pre-erythrocytic malaria vaccines with good preservation stability and immunostimulatory action.
| # | Name | Date |
|---|---|---|
| 1 | 202347005027.pdf | 2023-01-25 |
| 2 | 202347005027-STATEMENT OF UNDERTAKING (FORM 3) [25-01-2023(online)].pdf | 2023-01-25 |
| 3 | 202347005027-Sequence Listing in txt [25-01-2023(online)].txt | 2023-01-25 |
| 4 | 202347005027-Sequence Listing in PDF [25-01-2023(online)].pdf | 2023-01-25 |
| 5 | 202347005027-PRIORITY DOCUMENTS [25-01-2023(online)].pdf | 2023-01-25 |
| 6 | 202347005027-FORM 1 [25-01-2023(online)].pdf | 2023-01-25 |
| 7 | 202347005027-DRAWINGS [25-01-2023(online)].pdf | 2023-01-25 |
| 8 | 202347005027-DECLARATION OF INVENTORSHIP (FORM 5) [25-01-2023(online)].pdf | 2023-01-25 |
| 9 | 202347005027-COMPLETE SPECIFICATION [25-01-2023(online)].pdf | 2023-01-25 |
| 10 | 202347005027-FORM-26 [31-01-2023(online)].pdf | 2023-01-31 |
| 11 | 202347005027-Proof of Right [16-02-2023(online)].pdf | 2023-02-16 |
| 12 | 202347005027-Correspondence_Assignment_27-02-2023.pdf | 2023-02-27 |
| 13 | 202347005027-Correspondence_Form 26_01-03-2023.pdf | 2023-03-01 |